Hoekman John 4
4 · IMPEL NEUROPHARMA INC · Filed Apr 29, 2021
Insider Transaction Report
Form 4
Hoekman John
Chief Scientific Officer
Transactions
- Conversion
Common Stock
2021-04-27+4,523→ 108,496 total - Exercise of In-Money
Series A-2 Preferred Stock
2021-04-27+8,523→ 69,657 total→ Common Stock (504 underlying) - Other
Common Stock
2021-04-27−275→ 108,221 total - Conversion
Series A-2 Preferred Stock
2021-04-27−69,657→ 0 total→ Common Stock (4,523 underlying) - Exercise of In-Money
Series A-2 Warrants
2021-04-27$8.19/sh−8,523$69,803→ 0 total→ Series A-2 Preferred Stock (504 underlying)
Footnotes (4)
- [F1]The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
- [F2]Represents the number of shares that were withheld by the issuer in satisfaction of the exercise price of the warrants listed in Table II and does not represent a sale of securities by the reporting person.
- [F3]The warrant has a net exercise provision under which the holder, in lieu of paying the exercise price in cash, surrendered the warrant and received a net number of shares of common stock based on the $15.00 initial public offering price, after deducting the aggregate exercise price.
- [F4]The warrant is exercisable at any time at the holder's election on a one-for one basis and expires immediately prior to the closing of the issuer's IPO if not earlier exercised.